Cash Flow Statement

Altimmune (ALT) Retained Earnings (2010 - 2026)

Altimmune (ALT) reported Retained Earnings of -$5.2 million for Q1 2026, down 4.42% year-over-year from -$5.5 million in Q1 2025, and down 6.01% on a QoQ basis from -$4.9 million in Q4 2025.

Altimmune (ALT) has 17 years of Retained Earnings data on file, last reported at -$5.2 million in Q1 2026.

  • Quarterly Retained Earnings fell 4.42% year-over-year to -$5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.2 million (down 4.42% YoY) and the FY2025 annual result came in at -$4.9 million, up 0.9% from the prior year.
  • Retained Earnings slipped to -$5.2 million in Q1 2026 per ALT's latest filing, from -$4.9 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$4.8 million in Q3 2024 and bottomed at -$515.4 million in Q2 2024.
  • The 5-year median for Retained Earnings is -$5.2 million (2026), against an average of -$150.3 million.
  • The widest annual swing landed in 2024, when Retained Earnings slumped 9520.17%; it then soared 99.02% in 2025.
  • Tracing ALT's Retained Earnings over 5 years: stood at -$5.2 million in 2022, then advanced by 4.27% to -$5.0 million in 2023, then gained by 0.62% to -$5.0 million in 2024, then grew by 0.9% to -$4.9 million in 2025, then decreased by 6.01% to -$5.2 million in 2026.
  • Per Business Quant, the three latest ALT Retained Earnings figures stand at -$5.2 million (Q1 2026), -$4.9 million (Q4 2025), and -$5.0 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Retained Earnings (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -211.85 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -153.89 Mn
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 1.00 Bn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -438.66 Mn
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -279.00 Mn
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 14.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn - 130.89 Mn
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 36.42 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -24.89 Mn
10 Altimmune 379.61 Mn 379.61 Mn - -5.22 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -5.22 Mn
Dec 31, 2025 -4.93 Mn
Sep 30, 2025 -5.02 Mn
Jun 30, 2025 -5.04 Mn
Mar 31, 2025 -5.00 Mn
Dec 31, 2024 -4.97 Mn
Sep 30, 2024 -4.85 Mn
Jun 30, 2024 -515.37 Mn
Mar 31, 2024 -490.73 Mn
Dec 31, 2023 -5.00 Mn
Sep 30, 2023 -434.69 Mn
Jun 30, 2023 -414.02 Mn
Mar 31, 2023 -5.10 Mn
Dec 31, 2022 -5.23 Mn
Sep 30, 2022 -5.30 Mn
Jun 30, 2022 -332.71 Mn
Mar 31, 2022 -312.60 Mn
Dec 31, 2021 -293.17 Mn
Sep 30, 2021 -5.04 Mn
Jun 30, 2021 -235.77 Mn
Mar 31, 2021 -210.94 Mn
Dec 31, 2020 -5.04 Mn
Sep 30, 2020 -5.04 Mn
Jun 30, 2020 -158.03 Mn
Mar 31, 2020 -5.05 Mn
Dec 31, 2019 -137.38 Mn
Sep 30, 2019 -5.02 Mn
Jun 30, 2019 -5.04 Mn
Mar 31, 2019 -5.04 Mn
Dec 31, 2018 -5.04 Mn
Sep 30, 2018 -5.04 Mn
Jun 30, 2018 -5.04 Mn
Mar 31, 2018 -80.86 Mn
Dec 31, 2017 -4.58 Mn
Sep 30, 2017 -4.71 Mn
Jun 30, 2017 -5.74 Mn
Dec 31, 2016 -31.26 Mn
Sep 30, 2016 12,346.00
Jun 30, 2016 -216.91 Mn
Mar 31, 2016 -224.95 Mn
Dec 31, 2015 -223.72 Mn
Sep 30, 2015 -222.49 Mn
Jun 30, 2015 -221.16 Mn
Mar 31, 2015 -218.82 Mn
Dec 31, 2014 -229,528.00
Jun 30, 2014 -213.03 Mn
Mar 31, 2014 -212.59 Mn
Dec 31, 2013 -210.33 Mn
Sep 30, 2013 -205.90 Mn
Jun 30, 2013 -201.96 Mn
Mar 31, 2013 -200.72 Mn
Dec 31, 2012 -198.61 Mn
Sep 30, 2012 -197.34 Mn
Jun 30, 2012 -197.13 Mn
Mar 31, 2012 -196.37 Mn
Dec 31, 2011 -193.69 Mn
Sep 30, 2011 -194.44 Mn
Jun 30, 2011 -194.41 Mn
Dec 31, 2010 -189.89 Mn